Clinical Effect of Liraglutide in Treatment of Male Patients with Obese Diabetic Mellitus and Hypogonadism
Objective:To investigate the clinical effect of Liraglutide in the treatment of male patients with obese diabetes mellitus and hypogonadism.Method:A total of 120 male patients with obese diabetes mellitus and hypogonadism who admitted to the Endocrinology Department of Changzhou Hospital of Traditional Chinese Medicine from March 2020 to March 2023 were selected as the study objects and divided into two groups according to treatment methods,with 60 cases in each group.The control group was given conventional symptomatic treatment and Metformin to regulate blood glucose,and the observation group was given Liraglutide combined treatment on the basis of the control group,and both groups were observed for 3 months.Glucose metabolism indexes[fasting blood glucose(FPG),glycated hemoglobin(HbA1c),insulin resistance index(HOMA-IR),islet beta cell function index(HOMA-β)],lipid metabolism indexes[total cholesterol(TG),low density lipoprotein cholesterol(LDL-C),high density lipoprotein cholesterol(HDL-C)],renal function index[cystatin C(Cys C),random urinary albumin/creatinine ratio(UACR)],testosterone level(total testosterone,free testosterone)before and after treatment and androgen deficiency scale(ADAM)positive rate in middle-aged and elderly men were compared between the two groups.Result:Before treatment,there were no statistically significant differences between two groups in glycemic metabolism,lipid metabolism,renal function and testosterone levels(P>0.05).After treatment,the levels of FPG,HbA1c,HOMA-IR,TG,LDL-C and UACR were lower than before treatment,while the levels of Cys C,HOMA-β and HDL-C were higher than before treatment,the levels of FPG,HbA1c,HOMA-IR,TG,LDL-C and UACR in the observation group were lower than those in the control group,while the levels of Cys C,HOMA-β and HDL-C were higher than those in the control group,the differences were statistically significant(P<0.05).After treatment,the levels of total testosterone and free testosterone in the observation group were higher than those before treatment,and the differences were statistically significant(P<0.05).The positive rate of ADAM in observation group was lower than that in control group,and the difference was statistically significant(P<0.05).Conclusion:The treatment effect of glucagon-like peptide-1 receptor agonist in male patients with obesity diabetes mellitus and hypogonadism is good,which can effectively control the blood glucose level of patients,improve insulin resistance,lipid metabolism and kidney function,increase the testosterone level of patients,and reduce the positive rate of ADAM.
Type 2 diabetes mellitusObesity/overweightHypogonadismLiraglutide
国家科技期刊平台
NSTL
万方数据
